| Prev Close | 26.87 |
| Day Low/High | 26.77 / 27.77 |
| 52 Wk Low/High | 14.81 / 37.95 |
| Avg Volume | 857.60K |
Portola Pharmaceuticals Inc. (PTLA)
27.21
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 76.36M |
| Market Cap | 2.05B |
| EPS | -5.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Insider Buys of 2 Down Stocks Catch My Eye
Big insider purchases at Portola Pharmaceuticals and Alta Mesa Resources could be revealing.
A Rash of Biotech News
The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades. A rash of biotech news hitting t...
Portola Shares Lower After Update on Anticoagulant Launch -- Biotech Movers
The South San Francisco, Calif.-based firm said after the market close on Tuesday that the FDA has extended the review period for the company's prior approval supplement for Bevyxxa (betrixaban).
Tuesday Swoon Won't Change Most People's Market Views
I have little to add to my opening missive and what I have been saying for months -- that the markets have under priced risk and that the potential downside may dramatically exceed upside opportunity and reward (by about a factor of 3.5x). Today's...
Cramer: Don't Risk It All on a Small Biotech Unless You're Willing to Lose It All
Without at least one approved drug, I am tempted to say you should just take a pass.
These 3 Small Biotechs Have a Healthy Shot
Several firms hiked price targets on Portola into the $70s this week.
Give These 3 Small Biotechs a Shot
Several firms hiked price targets on Portola into the $70s this week.
Could These 9 Drugs Gain FDA Approval in the Age of Trump?
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
The firms all have drugs they want the feds to bend the rules to approve.
4 Small-Cap Biotech Stars
I'm still enthusiastic about the sector, but it is critical to also be prudent.
4 Small-Cap Biotech Stars
I'm still enthusiastic about the sector, but it is critical to also be prudent.
Synergy, Portola Still in My Sights
Both pharma companies are promising names that easily could become buyout targets.
Biotech Poised for Rebound
If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.
Biotech Poised for Rebound
If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.
A Biotech Trio to Like Going Into 2017
Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.
My Takeaways and Observations (2:45 p.m. EST edition)
"First gear, it's all right (Honda, Honda, go faster, faster) Second gear, I'll lean right (Honda, Honda, go faster, faster) Third gear, hang on tight (Honda, Honda, go faster, faster) Faster, it's all right." -- Beach Boys, "Little Honda" With a b...
My Takeaways and Observations
What a strange day -- maybe even ominous. This table tells it all. The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...
My Takeaways and Observations
The important messages today are the developing divergences. The strength in energy stocks (reflecting a $3.88 a barrel rise in crude oil) masked the underlying weakness in the broader markets. Stated simply, these divergences in breadth, highs/l...
My Takeaways and Observations (3:30 p.m. Edition)
It may be time to embrace the contrary. First issue (!!): The Palm Beach Chronicles. My weekly (brief) technical review of the markets -- cooling off ahead? BTIG's Stockton is bullish and so, as I have expressed, are most others! Campbell ...
Retail, Financials, Speculative Biotechs Getting Hit
This morning I warned about an overbought group of market sectors/leaders. Thus far, (recent leaders) retail and financials are being taken out to the woodshed. Speculative biotech, like Intrexon , Portola Pharmaceuticals , SAGE Therapeutics ...
My Takeaways and Observations
"Dougie, take what Mr. Market gives you." -- Grandma Koufax And I did, Grandma Koufax. A consecutive nine-day market drop was snapped as we regained most that was lost in that period. Today was a great day. (Boy, would I like to annualize the pe...
My Takeaways and Observations (Early Edition)
I have been warning about weakening breadth and narrow leadership for weeks and months. What have we gotten? Eight straight days (in a row) down for the first time since 2008. But, with stocks suffering from election uncertainties and given the ...
The Good, the Bad and the Ugly
"You see, in this world there's two kinds of people, my friend: Those with loaded guns and those who dig. You dig." -- Blondie in "The Good, the Bad and the Ugly." I did very little today. Markets were higher from the get-go and seemed "stuck" nea...
Underlying Risks in Speculative Bio Techs Can't Be Overstated
I have followed Novavax for several years. After yesterday's market close the company announced the results of their Phase Three trial for a respiratory-virus drug. NVAX missed its goal, and the shares are trading down by about 80% ($8.40 to $1) i...
How to Play It When the FDA Slams Your Stock
Here are three recent examples of how the patient can profit.
5 Small-Cap Biotechs With Big Potential
These 5 stocks all have positive catalysts on the horizon.
